1)Aiello LP, Avery RL, Arrigg PG et al:Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331:1480-1487, 1994
2)Adamis AP, Shima DT, Tolentino MJ et al:Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol 114:66-71, 1996
3)Jorge R, Costa RA, Calucci D et al:Intravitreal bevacizumab(Avastin)for persistent new vessels in diabetic retinopathy(IBEPE study). Retina 26:1006-1013, 2006
4)Spaide RF, Fisher YL:Intravitreal bevacizumab(Avastin)treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina26:275-278, 2006
5)Avery RL, Pearlman J, Pieramici DJ et al:Intravitreal bevacizumab(Avastin)in the treatment of proliferative diabetic retinopathy. Ophthalmology113:1695-1705, 2006
6)Nussenblatt RB, Palestine AG, Chan CC et al:Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology92:467-471, 1985
7)Haritoglou C, Kook D, Neubauer A et al:Intravitreal bevacizumab(Avastin)therapy for persistent diffuse diabetic macular edema. Retina 26:999-1005, 2006
8)Martidis A, Duker JS, Greenberg PB et al:Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 109:920-927, 2002
9)Jonas JB, Kreissig I, Sofker A et al:Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol 121:57-61, 2003